Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

2.360 -0.090 (-3.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Lexicon Pharmaceuticals Q2 Earnings Call Highlights ↗
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III... 
Via MarketBeat
Topics Earnings
Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses Estimates ↗
Via Chartmill
News headline image
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally ↗
Via Chartmill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss ↗
Via Chartmill
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Beats Q4 Estimates and Strengthens Cash Runway ↗
Via Chartmill
News headline image
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up. 
Via The Motley Fool
News headline image
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
Lexicon (LXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends ↗
Via Chartmill
News headline image
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Q1 Earnings Call Highlights ↗
Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter... 
Via MarketBeat
Topics Earnings
News headline image
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
$55 million funded at closing to repay existing loan facility 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney function 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon (LXRX) Q4 2025 Earnings Call Transcript ↗
Lexicon (LXRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Proposed Public Offering of Common Stock
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.